Trial 0C-18-19

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination with Atezolizumab in Patients with Specific HER2-Positive Advanced or Metastatic Solid Tumors

Type: Treatment
Phase: Phase I
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Anthony El-Khoueiry, M.D.
Other Trial Staff: Yan Ning, D.M., Cristina De Leon, Coordinator, Deborah Fridman, Coordinator, Lorraine Martinez, Coordinator, Chi Nguyen, Coordinator, Maria Sharma, Coordinator, Leila Andres, Coordinator, Nicole Jensen, Coordinator, Rishi Bhavsar, Coordinator, Marisabel Hurtado Castillo, Coordinator, Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Taison Tran, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Sodech Kim, Coordinator, Atessa Kiani, Coordinator, Kseniia Kulakova, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.